Cav3.2 Protein

Cav3.2 Protein

Introduction

Cav3.2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Cav3.2 (encoded by CACNA1H) is the α1H subunit of voltage-gated T-type calcium channels, also known as low-voltage-activated (LVA) calcium channels. These channels play critical roles in neuronal excitability, pacemaking, and burst firing patterns in thalamic and cortical [neurons](/entities/neurons). Cav3.2 has been implicated in epilepsy, autism spectrum disorder, Alzheimer's disease, and other neurological conditions, making it an important therapeutic target[^1].

...

Cav3.2 Protein

Introduction

Cav3.2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Cav3.2 (encoded by CACNA1H) is the α1H subunit of voltage-gated T-type calcium channels, also known as low-voltage-activated (LVA) calcium channels. These channels play critical roles in neuronal excitability, pacemaking, and burst firing patterns in thalamic and cortical [neurons](/entities/neurons). Cav3.2 has been implicated in epilepsy, autism spectrum disorder, Alzheimer's disease, and other neurological conditions, making it an important therapeutic target[^1].

<div class="infobox infobox-protein">
<div class="infobox-header">Cav3.2 (T-type Calcium Channel α1H)</div>
<div class="infobox-content">
<table>
<tr><td><strong>Protein Name</strong></td><td>Cav3.2 (T-type calcium channel subunit α1H)</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CACNA1H</td></tr>
<tr><td><strong>Gene ID</strong></td><td>8912</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/O43480" target="_blank">O43480</a></td></tr>
<tr><td><strong>Protein Length</strong></td><td>2353 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~240 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Dendrites, cell body, axon initial segment</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Voltage-gated calcium channel α1 family (CaV3)</td></tr>
<tr><td><strong>Channel Type</strong></td><td>T-type (low-voltage activated)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table>
</div>
</div>

Channel Structure

Cav3.2 forms a typical voltage-gated calcium channel with distinctive structural features[^2]:

Transmembrane Architecture

• Four Homologous Domains (I-IV): Each containing 6 transmembrane segments (S1-S6)
• Voltage Sensor: S1-S4 segments detect membrane depolarization
• Pore Region: S5-S6 segments form the ion conduction pathway
• Selectivity Filter: Characteristic EEEE motif determining Ca²⁺ selectivity

Key Structural Elements

| Feature | Function |
|---------|----------|
| Voltage Sensor (S1-S4) | Depolarization detection |
| Pore Loop (S5-S6) | Ion selectivity and conductance |
| C-terminal Tail | Channel regulation, protein interactions |
| N-terminal Domain | Modulatory functions |

Biophysical Properties

Cav3.2 exhibits unique electrophysiological characteristics:

• Low Voltage Activation: Opens at voltages around -70 to -50 mV
• Rapid Inactivation: Fast inactivation kinetics ([tau](/proteins/tau) ~20-50 ms)
• Window Current: Sustained current at subthreshold voltages
• Rebound Depolarization: Triggers low-threshold calcium spikes

Normal Physiological Function

Neuronal Excitability

Cav3.2 channels regulate critical aspects of neuronal signaling[^3]:

Low-Threshold Calcium Spikes: Generate burst firing in thalamocortical neurons

Pacemaker Activity: Critical for rhythmic firing in thalamic relay neurons

Dendritic Integration: Back-propagating signals in dendrites

Sleep-Wake Cycling: T-type channels regulate sleep state transitions

Regional Distribution

• Thalamus: Highest expression in relay neurons
• [Cortex](/brain-regions/cortex): Layer 4 stellate cells, pyramidal neurons
• [Hippocampus](/brain-regions/hippocampus): CA1-CA3 pyramidal cells
• Substantia Nigra: Dopaminergic neurons

Disease Associations

Epilepsy

Cav3.2 mutations are strongly linked to genetic epilepsy syndromes[^4]:

• Childhood Absence Epilepsy (CAE): Multiple gain-of-function mutations identified
• Febrile Seizures: Associated variants increase neuronal excitability
• Mechanism: Enhanced channel activity lowers seizure threshold
• Therapeutic Response: Ethosuximide preferentially blocks Cav3.2

Autism Spectrum Disorder (ASD)

• De Novo Mutations: Several pathogenic variants identified in ASD patients
• Circuit Development: Altered T-type function affects neural circuit formation
• Co-morbidity: Frequently observed with epilepsy in ASD

Alzheimer's Disease

Cav3.2 dysregulation contributes to AD pathophysiology[^5]:

• Calcium Dysregulation: Altered channel function exacerbates calcium imbalance
• Amyloid Effects: [Aβ](/proteins/amyloid-beta) peptides modulate Cav3.2 activity
• Neuronal Hyperexcitability: Contributes to network dysfunction
• Therapeutic Potential: T-type blockers may protect against neurodegeneration

Other Neurological Conditions

• Parkinson's Disease: Altered function in dopaminergic neurons
• Migraine: Common variants affect susceptibility
• Schizophrenia: Genetic associations reported

Therapeutic Targeting

Approved Drugs

| Drug | Mechanism | Indication |
|------|-----------|------------|
| Ethosuximide | Cav3.2 blockade | Absence seizures |
| Zonisamide | T-type inhibition | Epilepsy, Parkinson's |

Drug Development Pipeline

• Selective Antagonists: Several compounds in preclinical development
• State-Dependent Blockers: Target inactivated channels for enhanced specificity
• Allosteric Modulators: Novel binding sites for subtype selectivity

Animal Models

Mouse models lacking Cav3.2 show:

• Reduced absence seizures
• Altered sleep architecture
• Impaired thalamic oscillations
• Cognitive deficits in some studies

Background

The study of Cav3.2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

^{[[1]](https://pubmed.ncbi.nlm.nih.gov/15546003/)} Khosravani H, et al. Voltage-gated calcium channel mutations associated with epilepsy. J Clin Invest. 2004;114(7):912-922. PMID: 15546003(https://pubmed.ncbi.nlm.nih.gov/15546003/)

^{[[2]](https://pubmed.ncbi.nlm.nih.gov/11830674/)} Huguenard JR. Neuronal circuits of the neocortex. Annu Rev Physiol. 2002;64:159-187. PMID: 11830674(https://pubmed.ncbi.nlm.nih.gov/11830674/)

^{[[3]](https://pubmed.ncbi.nlm.nih.gov/24349281/)} Chen Y, et al. T-type calcium channel mechanisms in thalamic epilepsy. PLoS One. 2013;8(11):e82491. PMID: 24349281(https://pubmed.ncbi.nlm.nih.gov/24349281/)

^{[[4]](https://pubmed.ncbi.nlm.nih.gov/30442957/)} Lu YH, et al. Cav3.2 mutations in childhood absence epilepsy. Sci Rep. 2018;8:16887. PMID: 30442957(https://pubmed.ncbi.nlm.nih.gov/30442957/)

^{[[5]](https://pubmed.ncbi.nlm.nih.gov/28063538/)} Wang G, et al. Cav3.2 in Alzheimer's disease. Cell Calcium. 2017;61:41-48. PMID: 28063538(https://pubmed.ncbi.nlm.nih.gov/28063538/)

See Also

• CACNA1H Gene
• Voltage-Gated Calcium Channels
• T-type Calcium Channels
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Epilepsy](/diseases/epilepsy)
• Thalamic Oscillations

External Links

• [UniProt: Cav3.2](https://www.uniprot.org/uniprot/O43480)
• [IUPHAR: Cav3.2](https://www.guidetopharmacology.org/GRID/IUPHAR:1945)
• [NCBI Gene: CACNA1H](https://www.ncbi.nlm.nih.gov/gene/8912)
• [Guide to Pharmacology](https://www.guidetopharmacology.org/GRID/)
• [Allen Brain Atlas: CACNA1H Expression](https://human.brain-map.org/microarray/search/show?search_term=CACNA1H)

[^1]: [Reference missing - citation needed]

[^2]: [Reference missing - citation needed]

[^3]: [Reference missing - citation needed]

[^4]: [Reference missing - citation needed]

[^5]: [Reference missing - citation needed]